-20C

p70 S6 Kinase 2 Antibody





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W. IP	Reactivity: H M R	Sensitivity: Endogenous	MW (kDa): 60	Source/Isotype: Rabbit	UniProt ID: #O9UBS0	Entrez-Gene Id: 6199
Product Usage Information		Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				ycerol. Store at –
Specificity/Sen	sitivity	p70 S6 Kinase 2 Antibody recognizes endogenous levels of total p70 S6 kinase 2 (S6K2) protein. T antibody does not cross-react with p70 S6 kinase 1 (S6K1) protein.		2) protein. This		
Source / Purific	ation		Pro435 of human p	munizing animals with a with a with a more service of the service		
Background		cycle progression (1,2) is involved in translatic kinase, is derived from the amino terminus, w activated signaling pat rapamycin, FRAP/mTO kinase is controlled by pseudosubstrate doma linker domain are mos correlates with p70 kin of phosphoinositide 3- is stimulated by growtl coupled receptor ligan (FRAP/mTOR inhibitor) pseudosubstrate regio of pseudosubstrate su Ser371, is an <i>in vitro</i> su resistant mutant p70 S p70 S6 kinase 2 (S6K2) with p70 S6 kinase (S6 sensitive S6 kinase act from S6K1 (11,12). Res	. p70 S6 kinase pho onal control of 5' ol on the same gene an <i>t</i> hich encode a nucc thway downstream R, a pathway distin multiple phosphory ains (1). Phosphory at critical for kinase hase activity <i>in vivo</i> dependent proteir h factors such as ir lofs, and is blocked of (1,6,7). Ser411, Th on (1). Phosphoryla ppression (1,2). An ubstrate for mTOR 56 kinase (8). exhibits high hom K1). Similar to S6K ² ivity (9,10). S6K2 ha earch studies show	Thr protein kinase that i psphorylates the S6 prot igopyrimidine tract mRN d is identical to p70 S6 k lear localizing signal (1). of phosphoinositide-3 k let from the Ras/MAP kir ylation events located w lation of Thr229 in the c function (1). Phosphory (3). Prior phosphorylation isolin, EGF and FGF, as w by wortmannin, LY29400 r421 and Ser424 lie with tion at these sites is tho other LY294002 and rap and correlates well with sology in the kinase dom l, S6K2 displays both mit as been shown to have r of that S6K2 is commonly ssues, and may promote	ein of the 40S ribosi JAS (1). A second iso cinase except for 23 Both isoforms lie or cinase (PI-3K) and the nase cascade (1). The vithin the catalytic, li atalytic domain and lation of Thr389, ho on of Thr389 is requ 229 (4,5). Phosphory vell as by serum and 02 (PI-3K inhibitor) a in a Ser-Pro-rich regu ught to activate p70 amycin sensitive ph the activity of a par ain and adjacent reg togen-dependent ar edundant as well as expressed at highe	omal subunit and oform, p85 S6 extra residues at in a mitogen the target of e activity of p70 S6 inker and d Thr389 in the wever, most closely irred for the action ylation of this site d some G-protein- and rapamycin gion located in the S6 kinase via relief iosphorylation site, tially rapamycin gulatory region nd rapamycin- e distinct functions r levels in tumor
Background Re	ferences	1. Pullen, N. and Thom 2. Dufner, A. and Thom 3. Weng, Q.P. et al. (199 4. Pullen, N. et al. (199 5. Alessi, D.R. et al. (199 6. Polakiewicz, R.D. et al 7. Fingar, D.C. et al. (200 9. Gout, I. et al. (1998) 10. Lee-Fruman, K.K. et 11. Pende, M. et al. (20 12. Pardo, O.E. et al. (2 13. Sridharan, S. and B 14. Pardo, O.E. and Sec	nas, G. (1999) Exp (98) J Biol Chem 273 8) Science 279, 707 98) Curr Biol 8, 69- al. (1998) J Biol Che 02) Genes Dev 16, 12) J Biol Chem 277, J Biol Chem 273, 30 t al. (1999) Oncoge 104) Mol Cell Biol 24 006) EMBO J 25, 30 asu, A. (2011) Can	Tell Res 253, 100-9. 9, 16621-9. 10. 81. 172, 23534-41. 1472-87. 20104-12. 0061-4. 14, 3112-24. 78-88. Ter Res 71, 2590-9.		

Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).		
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.		
Applications Key	W: Western Blotting IP: Immunoprecipitation		
Cross-Reactivity Key	H: Human M: Mouse R: Rat		
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.		
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.		
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.		
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purpose, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.		